首页> 外文期刊>World Allergy Organization Journal >A Novel Phenotype of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity The High-Risk Patient
【24h】

A Novel Phenotype of Nonsteroidal Anti-Inflammatory Drug Hypersensitivity The High-Risk Patient

机译:非甾体类抗炎药超敏反应的新型表型高危患者

获取原文
       

摘要

Background Some nonsteroidal anti-inflammatory drug (NSAID)-hypersensitive patients develop adverse reactions when challenged with weak cyclooxygenase 1 (COX-1) inhibitors. Objectives To investigate the prevalence and clinical features of this high-risk population. Materials and methods Patients from 2 outpatient allergy clinics consulting between October 2005 and October 2007 because of adverse reactions to classic NSAIDs were submitted to confirmatory double-blind oral challenges with the suspected NSAID and with acetaminophen, preferential and/or specific COX-2 inhibitors. Patients were then classified as low-risk and high-risk groups according to the results of provocation tests. Results Three hundred three patients were studied: 179 (59.0%) were tolerant to acetaminophen and the selective COX-2 inhibitors (low-risk group), whereas 124 (40.9%) developed reactions to at least one of the ''low COX-1 inhibitors'' (high-risk group). No distinctive demographic or clinical characteristics were present when both groups of patients were compared. Conclusions A large proportion of patients sensitive to classic NSAIDs cannot tolerate the weak COX-1 inhibitors. Oral challenges should be performed by trained specialists to advise these patients about the use of NSAIDs.
机译:背景技术一些非甾体类抗炎药(NSAID)过敏的患者在接受弱的环氧合酶1(COX-1)抑制剂刺激时会产生不良反应。目的探讨该高危人群的患病率和临床特征。材料和方法2005年10月至2007年10月间,来自两家门诊过敏诊所的患者因对经典NSAID的不良反应而接受咨询,接受了怀疑的NSAID以及对乙酰氨基酚,优先和/或特定COX-2抑制剂的确诊性双盲口服挑战。然后根据激发试验的结果将患者分为低风险和高风险组。结果研究了303名患者:179名(59.0%)耐受对乙酰氨基酚和选择性COX-2抑制剂(低风险组),而124名(40.9%)对至少一种“低COX- 1种抑制剂''(高风险组)。比较两组患者时,没有明显的人口统计学或临床特征。结论大部分对经典NSAID敏感的患者不能耐受弱COX-1抑制剂。应由训练有素的专家进行口服挑战,以建议这些患者使用NSAIDs。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号